IA期非小细胞肺癌癌症患者的长期预后

Q4 Medicine
Shun-Ichi Watanabe
{"title":"IA期非小细胞肺癌癌症患者的长期预后","authors":"Shun-Ichi Watanabe","doi":"10.2482/haigan.62.971","DOIUrl":null,"url":null,"abstract":"━━ In recent years, long-term prognostic observations of five years or more for early-stage lung cancer have revealed that deaths from other diseases (secondary cancer deaths+non-cancer deaths) account for a considerable proportion of all deaths. In the era of medical advances, achieving a survival of five years after surgery is not the only goal for early-stage lung cancer, for which a good long-term prognosis can be expected. In the future, details of other disease deaths, i.e. what kind of cancer the patients suffered from and what kind of treatment they received in cases of death due to secondary cancers, or what kind of disease led to death due to non-cancer disease, should be confirmed over a much longer period of time than before. Given the above, we thoracic oncologists should evaluate how surgery, adjuvant chemotherapy, or adjuvant radiotherapy affect the long-term events (more than five years after treatment) and re-consider and improve our current treatment strategy prop-erly. ( JJLC. 2022;62:971-974)","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Long-term Prognosis in Patients with Resected Stage IA Non-small-cell Lung Cancer\",\"authors\":\"Shun-Ichi Watanabe\",\"doi\":\"10.2482/haigan.62.971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"━━ In recent years, long-term prognostic observations of five years or more for early-stage lung cancer have revealed that deaths from other diseases (secondary cancer deaths+non-cancer deaths) account for a considerable proportion of all deaths. In the era of medical advances, achieving a survival of five years after surgery is not the only goal for early-stage lung cancer, for which a good long-term prognosis can be expected. In the future, details of other disease deaths, i.e. what kind of cancer the patients suffered from and what kind of treatment they received in cases of death due to secondary cancers, or what kind of disease led to death due to non-cancer disease, should be confirmed over a much longer period of time than before. Given the above, we thoracic oncologists should evaluate how surgery, adjuvant chemotherapy, or adjuvant radiotherapy affect the long-term events (more than five years after treatment) and re-consider and improve our current treatment strategy prop-erly. ( JJLC. 2022;62:971-974)\",\"PeriodicalId\":35081,\"journal\":{\"name\":\"Japanese Journal of Lung Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Lung Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2482/haigan.62.971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2482/haigan.62.971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

━━近年对早期肺癌五年或以上的长期预后观察显示,其他疾病(继发癌症死亡+非癌症死亡)在所有死亡中占相当大的比例。在医疗进步的时代,实现手术后5年的生存并不是早期肺癌的唯一目标,对于早期肺癌来说,可以期待一个良好的长期预后。未来,其他疾病死亡的细节,如继发性癌症死亡的患者患的是哪种癌症,接受了什么样的治疗,或者是哪种疾病导致了非癌症疾病的死亡,都应该在比以前更长的时间内得到证实。综上所述,我们胸腔肿瘤学家应该评估手术、辅助化疗或辅助放疗对长期事件(治疗后5年以上)的影响,并适当地重新考虑和改进我们目前的治疗策略。(JJLC。62:971 2022; 974)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Long-term Prognosis in Patients with Resected Stage IA Non-small-cell Lung Cancer
━━ In recent years, long-term prognostic observations of five years or more for early-stage lung cancer have revealed that deaths from other diseases (secondary cancer deaths+non-cancer deaths) account for a considerable proportion of all deaths. In the era of medical advances, achieving a survival of five years after surgery is not the only goal for early-stage lung cancer, for which a good long-term prognosis can be expected. In the future, details of other disease deaths, i.e. what kind of cancer the patients suffered from and what kind of treatment they received in cases of death due to secondary cancers, or what kind of disease led to death due to non-cancer disease, should be confirmed over a much longer period of time than before. Given the above, we thoracic oncologists should evaluate how surgery, adjuvant chemotherapy, or adjuvant radiotherapy affect the long-term events (more than five years after treatment) and re-consider and improve our current treatment strategy prop-erly. ( JJLC. 2022;62:971-974)
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
65
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信